Skip to main content
Category

Research

Exploring EGFR Mutations in Lung Cancer: Key Diagnostic & Management Strategies ResearchTreatments

Exploring EGFR Mutations in Lung Cancer: Key Diagnostic & Management Strategies

*April 2021* Lung cancer expert Dr. Pasi Janne, a professor of medicine at Harvard Medical School and a translational thoracic medical oncologist at the Dana-Farber Cancer Institute, speaks about EGFR treatments including post-progression following osimertinib. This is a very informative podcast and easy to understand. Listen to the podcast or read the…
cece
June 19, 2021
EGFR Resisters logo
EGFR Resisters Self-Funded Research Projects for 2021 ResearchTreatments

EGFR Resisters Self-Funded Research Projects for 2021

*March 2021* Want to know more details about our two self-funded EGFR Resisters research projects in partnership with LUNGevity? 1. TARGETING DRUG TOLERANT STATES + DNA DAMAGE TO BLOCK OSIMERTINIB RESISTANCE, conducted by Christine Lovly, MD, PhD Despite high tumor response rates, patients treated with EGFR targeted therapies, such as osimertinib, inevitably…
cece
June 19, 2021
EGFR Resisters logo
EGFR Resisters and LUNGevity Foundation Partner on Lung Cancer Research Award FundingPartnersResearchTreatments

EGFR Resisters and LUNGevity Foundation Partner on Lung Cancer Research Award

*February 2021* WASHINGTON, Feb. 19, 2021 /PRNewswire/ -- Patient group EGFR Resisters and LUNGevity Foundation today announced the 2021 recipients of the first EGFR Resisters/LUNGevity Lung Cancer Research Award. This award program, driven by EGFR Resisters—a grassroots patient-led group that has 2,500+ patients and caregivers from 75+ countries—supports critical research that seeks to…
cece
June 19, 2021
Targeted Oncology
Osimertinib Penetrates Blood-Brain Barrier and Decreases Metastasis in EGFR+ NSCLC ResearchTreatments

Osimertinib Penetrates Blood-Brain Barrier and Decreases Metastasis in EGFR+ NSCLC

*February 2021* In EGFR-mutant non–small cell lung cancer (NSCLC) and brain metastases, oral osimertinib (Tagrisso) achieved rapid, high, and uniform brain exposure which was followed reduction in total brain metastases volume, according to results from the phase 1 ODIN-BM study (NCT03463525). A presentation on osimertinib given during the 2020 World…
cece
March 22, 2021
EGFR TKI Combination Therapies: C797S, MEK, AURORA Kinase ResearchTreatments

EGFR TKI Combination Therapies: C797S, MEK, AURORA Kinase

*February 2021* Highlights from Dr. Collin Blakely's presentation: EGFR TKI Combination Therapies: C797S, MEK, AURORA Kinase at the 2021 Targeted Therapies Conference: EGFR C797S is the predominant on-target resistance mutation Osimertinib + gefitinib prevents acquired second-site EGFR resistance mutations in preclinical models 1 st line Osimertinib + Gefitinib is well-tolerated…
cece
March 22, 2021
OncLive
New Designations and Efficacy Demonstrations Push the EGFR+ NSCLC Paradigm Forward ResearchTreatments

New Designations and Efficacy Demonstrations Push the EGFR+ NSCLC Paradigm Forward

*January 2021* The utility of EGFR TKIs in select subgroups of patients with EGFR-mutant metastatic non–small cell lung cancer (NSCLC), as well as their role in the adjuvant setting, are beginning to be teased out, explained Timothy F. Burns, MD, PhD. “We have very good EGFR inhibitors,” said Burns. “When patients…
cece
March 22, 2021
OncLive
TKIs Set the Stage for Treatment in HER2-Mutant Lung Cancer ResearchTreatments

TKIs Set the Stage for Treatment in HER2-Mutant Lung Cancer

*January 2021* Poziotinib, mobocertinib (TAK-788), and fam-trastuzumab deruxtecan-nxki (Enhertu) are among some of the agents that have positioned HER2 as a must-test alteration in newly diagnosed advanced lung cancer, explained Lecia V. Sequist, MD, MPH, who added that the specificity of antibody-drug conjugates (ADCs) could challenge the broad activity of TKIs as…
cece
March 22, 2021
Targeted Oncology
Navigating Nuances in Early and Metastatic Lung Cancer Treatment ResearchTreatments

Navigating Nuances in Early and Metastatic Lung Cancer Treatment

*January 2021* The treatment paradigms of early-stage and metastatic lung cancer have expanded significantly in recent years with the addition of immunotherapy and targeted therapy options, said Brendon Stiles, MD, who added that challenges regarding screening, molecular testing, and localized therapy remain areas of ongoing research. “I tend to be…
cece
March 22, 2021